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ABSTRACT 
 
Aim 
The aim of this study is to compare the degree of severity of chronic periodontitis in HIV-
seropositive subjects with chronic periodontitis to control subjects with chronic periodontitis, 
in the Ga-Rankuwa area in South Africa. 
 
Methods 
Two cohorts of subjects with chronic periodontitis were recruited for this study over a period 
of time: thirty HIV-seropositive subjects; and 30 control subjects presumed to be HIV -
seronegative and apparently in good health.  
 
Results 
When all the periodontal indices were compared and evaluated there was no association 
between HIV-serostatus and the periodontal indices.  When periodontal indices were 
compared between HIV-seropositive subjects using highly active anti-retroviral therapy 
(HAART), and HAART-naïve subjects, there was no statistical differences regarding gingival 
recession, plaque index and bleeding index.  However, the mean pocket depth in HAART-
naïve seropositive subjects was slightly greater than in HIV-seropositive subjects using 
HAART.  Correlation coefficient of mean pocket depth in relation to log CD4+ T cell count 
in the HIV-seropositive  HAART-naïve group of subjects showed a significant negative 
correlation (P =  -0.947), but there was no correlation between the mean gingival recession 
values and the log CD4+ T cell counts in the same group (P=0.303).  For the HIV-
seropositive subjects using HAART the correlation coefficient test failed to show significant 
statistical relationships between log CD4+ T cell count and mean pocket depth (P=0.903) and 
mean gingival recession (P=0.312) in HIV-seropositive subjects using HAART. 
 
Conclusion 
HIV-seropositive subjects with chronic periodontitis show clinical manifestations of similar 
degree of their periodontal disease to those of healthy control subjects with chronic 
 vi
periodontitis, with no differences in the mean pocket depth, gingival recession, plaque index 
and bleeding index.   
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  CHAPTER 1 
 
1.0 INTRODUCTION  
 
The relationship between chronic periodontitis and HIV infection is not clear and a 
considerable difference in opinion exists regarding the prevalence of conventional chronic 
periodontitis among HIV-seropositive subjects (Holmstrup & Glick, 2002; Stanford & Rees, 
2003). Microbiological studies have failed to detect any major differences in the subgingival 
microbial flora of HIV-seropositive subjects with chronic periodontitis compared to HIV-
seronegative controls (Zambon, Reynolds & Genco, 1990; Moore, Moore & Riley, 1993) and 
the humoral immune response to the periodontopathic bacteria is similar in both groups 
(Yeung, Taylor & Sherson, 2002). 
    
Some authors reported a higher prevalence of periodontal attachment loss and a more rapid 
progression of periodontal disease over time in HIV-seropositive subjects compared to HIV-
seronegative controls (Tomar, Swango & Kleinman, 1995; Robinson, Scheiham & 
Challacombe, 1996; Robinson, Boulter & Birnbaum, 2000).  In addition, it has been reported 
that a great portion of the periodontal attachment loss seen in HIV-seropositive subjects with 
chronic periodontitis is expressed by the presence of localised recession, rather than the 
development of deep periodontal pockets as in conventional chronic periodontitis in HIV-
seronegative subjects (Robinson, et al., 1996; Robinson, 1997; McKaig, Patton & Thomas, 
2000; Ryder, 2002).  However, others failed to document differences between HIV-
seropositive and -seronegative subjects with chronic periodontitis regarding the natural course 
of the periodontal disease (Scheutz, et al., 1997; Matee, Nguvumali & Lembariti, 1999).  
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This considerable difference of opinion regarding the natural course of chronic periodontitis 
in HIV-seropositive subjects may be a cause of confusion in respect of the periodontal 
management of HIV-infected subjects. 
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CHAPTER 2 
 
2.0  AIMS OF THE STUDY 
 
• The aim of this study is to compare the degree of severity of chronic periodontitis in 
HIV-seropositive subjects with chronic periodontitis to control subjects with chronic 
periodontitis, in the Ga-Rankuwa area in South Africa. 
• Pocket depth (PD), gingival recession (GR), plaque index (PI) and bleeding index (BI) 
were compared by HIV-serostatus, the use of HAART, and CD4+ T cell count. 
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CHAPTER 3 
 
3.0 LITERATURE REVIEW 
 
3.1 Chronic periodontitis 
 
Periodontitis is defined as an “inflammatory disease of the supporting tissues of the teeth 
caused by specific micro-organisms, resulting in progressive destruction of the periodontal 
ligament and alveolar bone with pocket formation, recession or both” (Novak, 2006).  
Chronic periodontitis is the most frequent occurring form of periodontitis, occurs most 
commonly in adults, may affect a variable number of teeth, is associated with the presence of 
dentogingival plaque, and has a variable rate of progression (International workshop for the 
classification of periodontal disease.  Consensus Report, 1999). 
 
Chronic periodontitis can be further classified by the extent and severity.  Chronic 
periodontitis is defined as localised when ≤30% of sites are affected and generalised if >30% 
of sites are affected.  The severity of chronic periodontitis is determined by the amount of 
clinical attachment loss (CAL) and is catergorised into slight (1-2mm CAL), moderate (3-
4mm CAL) and severe (≥5mm CAL) (International workshop for the classification of 
periodontal disease.  Consensus Report, 1999). 
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3.2 Pathogenic mechanisms of chronic periodontitis 
 
3.2.1 Humoral and cellular immunity in chronic periodontitis 
 
While the dentogingival biofilm is critical to the development of chronic periodontitis, the 
vast majority of the periodontal tissue destruction that occurs in chronic periodontitis is the 
outcome of immunoinflammatory responses of the host to the dentogingival biofilm challenge 
rather than the outcome of the direct virulence effect of the periodontopathic bacteria 
(Marshall, 2004).  These responses may act as a double-edged sword: one edge is protective 
and fighting the periodontopathic micro-organism, while the other edge causes periodontal 
tissue destruction (Teng, 2003). 
 
Innate immune cells in the periodontium (macrophages, monocytes, natural killer cells, 
polymorphonuclear leukocytes, Langerhans cells and other dendritic cells, resident mucosal 
cells) become activated following their encounter with periodontopathic bacteria and produce 
and release a variety of proinflammatory cytokines (IL-1, IL-6, TNF-α) and inflammatory 
mediators (PGE2, matrix metalloproteinases), that singularly or in combination can cause 
extracellular matrix degradation and alveolar bone resorption (Zambon, 1996; Offenbacher, 
1996).  The innate immune cells, and the modified tissue environment (through the change in 
cytokine profile) subsequently activate naïve adaptive immune cells including T and B 
lymphocytes that generate an adaptive immune response (humoral and cell mediated) towards 
the periodontopathic bacteria (Zambon, 1996; Baker, 2000; Teng, 2003). 
 
The humoral immune response is mounted parallel to, and immediately after the innate 
response and is an early event in the response toward the periodontopathic bacteria.  Activated 
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B lymphocytes differentiate into plasma cells producing antibodies.  Antigen-specific 
antibodies are able to trigger complement-mediated lysis, antibody-dependent cytotoxicity, 
antibody dependent neutralisation and opsonisation.  These humoral responses against 
periodontopathic bacteria in the dentogingival biofilm are protective to the host and it is 
believed that the humoral arm of the immune system does not participate in periodontal tissue 
destruction.  However, it is not always effective (Kinane, Lappin & Koulouri, 1999, Kinane & 
Lappin, 2001; Teng, 2003).  If it is not successful in eradicating the periodontopathic bacteria, 
the cell mediated immune response is fully immobilised as a second line of defence to fight 
the periodontopathic bacteria (Offenbacher, 1996; Teng, 2003).   
 
It appears that CD8+ T cells do not have a direct role in fighting periodontal pathogens.  They 
may have an indirect protective role through regulating other components of the immune 
responses and fighting viruses within periodontal tissues, and it is likely that they do not 
contribute to periodontal tissue destruction during periodontal disease progression (Teng, 
2003).  On the other hand CD4+ T helper cells have a major role in the chain of events that 
lead to alveolar bone loss and periodontal disease progression (Theill, Boyle & Penninger, 
2002; Taubman, Valverde & Han, 2005). 
 
Following activation by dedicated antigen presenting cells (APC) (macrophages/monocytes, 
B lymphocytes, dendritic cells, Langerhans cells) which present periodontopathic bacterial 
antigens in the context of MHC class II molecules, CD4+ T helper (Th) cells can differentiate 
into two distinct subset phenotype : Th1 cells that express IL-12, IL-2, INF-γ and TNF-α/B   
(type 1 cytokines) and are primarily involved in cell mediated immunity, and Th2 cells that 
express  IL-4, IL-5, IL-6, IL-10 and IL-13 (type 2 cytokines), that are mainly involved in 
humoral (antibody-mediated) immune response (Taylor, Preshaw & Donaldson, 2004).  The 
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generation of a specific Th subtype (Th1 versus Th2) is complex  and depends on the type of 
cytokines present in the local micro-environment, the antigen type and dose, the 
characteristics of the APC presentation, among other factors (Spellberg & Edwards, 2001; 
Yamazaki & Nakajima, 2004).  The balance between Th1/Th2 cells in the periodontium is 
dynamic and may shift from one predominant subtype to the other depending on the local 
circumstances.  In the pathogenesis of periodontal disease this balance is important and 
dictates if the mounted immune response will protect the host against periodontal infection or 
will be pathogenic and contributes toward progressive periodontal tissue destruction 
(Seymour & Gemmel, 2001; Teng, 2003).   
 
There are conflicting reports in the literature regarding which type of the Th response is 
associated with a stable periodontal lesion versus a progressive one.  A number of studies 
support the view that Th2 type immune response is associated with a stable lesion while a Th1 
response is responsible for periodontal disease progression (Takeichi, Haber & Kawai, 2000; 
Taubman & Kawai, 2001).  However, other reports favour the concept that periodontal 
disease progression is associated with the predominance of Th2 type immune response 
(Gemmel & Seymour, 2004; Taylor, et al., 2004). 
 
In principle the immune system is employing Th1 type responses to protect the host against 
many bacterial infections, and it switches to a Th2 type response when the micro-organisms 
are cleared in order to re-establish homeostasis (Spellberg, et al., 2001).  It is reasonable to 
assume therefore, that in active periodontal disease, both Th1 and Th2 cytokine profiles will 
be expressed; Th1 type inflammatory cytokines mediate periodontal tissue destruction while 
Th2 type cytokines are engaged in tissue repair and homeostasis during the inflammatory 
process (Roberts, McCaffery & Michalek, 1997; Kinane, et al., 2001). 
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In any event, gingival lesions from subjects with chronic periodontitis demonstrate highly 
variable cytokine profile, and the lymphocytic cell population that infiltrate the diseased 
periodontal tissues changes with the progression of the specific inflammatory diseased sites 
(Yamazaki, et al., 2004). 
 
Both Th1 and Th2 cells with some of their associated cytokines are involved in alveolar bone 
loss during periodontal disease progression (Teng, 2002, Teng, 2003).  Th1 cell associated 
cytokines are involved in the production of pro-inflammatory cytokines (IL-1, TNF-α), that 
can mediate alveolar bone destruction while Th2 cell associated cytokines have anti-
inflammatory characteristics and are involved in the biological processes of tissue repair and 
remodeling (Kinane, et al., 2001; Teng 2003).  Furthermore, Th2 cells take part in the 
induction of B cell-mediated humoral immune response, that are protective against 
periodontal infection (Teng, 2003).  Th1 cell mediated immunity on the other hand, is 
characterised by a macrophage/T cell response.   
 
Interferon gamma (IFN-γ) secreted by Th1 cells activate macrophages to increase 
phagocytosis, oxidative burst metabolites, and intracellular killing of micro-organisms.  INF-γ 
also mediates the secretion of inflammatory substances and cytokines such as prostaglandins, 
TNF-α and IL-1 which perpetuates an inflammatory reaction that causes periodontal tissue 
damage (Yamazaki, et al., 2004).  Alteration in the balance of Th1/Th2 cytokines may shift 
the immune response away from protection of the host from periodontopathic infection, 
towards host derived periodontal tissue damage and progression of periodontal disease. 
 
Receptor activator of nuclear factor-κB (RANK) is a protein member of the TNF family.  It is 
present on the surface of osteoclasts and their precursor cells.  Its ligand (RANKL) can be 
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expressed on osteoblasts, T lymphocytes and bone marrow stromal cells.  In the presence of 
colony-stimulating factor-1 (CSF-1), RANK-RANKL interaction on osteoclast precursor 
generates activation and differentiation of osteoclasts and subsequent alveolar bone resorption 
(Teng, 2003; Taubman, et al., 2005).  Osteoprotegerin (OPG) is a soluble decoy receptor for 
RANKL, and by binding to RANKL, OPG inhibits osteoclastogenesis (Baker, 2000).  
RANKL – OPG interaction is regulated by hormones (Vitamin D, estrogen, glucocorticoids) 
and cytokines (TNF-α, IL-1, IL-4, IL-6), and the balance of this interaction dictates 
osteoblastogenic versus osteoclastogenic processes (Theill, et al., 2002; Teng, 2003). 
 
Periodontopathic bacteria trigger the expression of RANKL on CD4+ T helper cells that 
result in osteoclast activation and alveolar bone loss during periodontal disease progression 
(Teng, 2003; Taubman, et al., 2005).  In addition, activated T cells produce cytokines such as 
TNF-α, IL-11, IL-17 and INF-γ that lead to increased RANKL expression on osteoblasts.  
This results in T cell-mediated indirect alveolar bone resorption (Taubman, et al., 2005).  In 
addition, INF-γ secreted by CD4+ Th1 cells can upregulate the expressions of MHC class II 
and other regulatory molecules on APC, leukocytes and mesenchymal cells, which may 
further recruit other signaling molecules associated with bone remodeling (Teng, 2003). 
 
 
3.3 Periodontopathic bacteria and chronic periodontitis 
 
The microbial flora of periodontal lesions in HIV-seronegative and -seropositive subjects is 
similar regarding the periodontopathic bacteria that populate the dentogingival biofilm.  The 
periodontopathic bacteria are mainly gram-negative anaerobes and include Porphyromonas 
gingivalis,  Fusobacterium nucleatum, Actinobacillus actinomycetemcomitans, Eikenella 
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coroddens, Wolinella recta, among other species (Robinson, Adegboye & Rowland, 2002); 
and HIV-seropositive subjects with chronic periodontitis do not harbour higher counts of 
periodontopathic bacteria (Ģoncalves, Ferreira & Silva, 2005).  
 
However, HIV-seropositive subjects show elevated levels of opportunistic bacteria in their 
oral cavities that usually are not implicated in the development and progression of chronic 
periodontitis, and elevated levels of fungal and viral micro-organisms (Ryder, 2002).  Some 
extra-oral bacterial species, not common in HIV-seronegative subgingival microflora can be 
found in HIV-seropositive subjects and include Enterobacteria spp, Pseudomonas 
aeruginosa, Clostridium difficile, Clostridium clostridiiforme and Mycoplasma salivarium 
(Robinson, et al., 2002). 
 
The significance of the presence of these extra-oral micro-organisms regarding the 
pathogenesis and the clinical manifestation of chronic periodontitis in HIV-seropositive 
subjects is difficult to determine. 
 
 
3.4  Antigen presenting dendritic cells and periodontitis 
 
Dendritic cells (DC) are dedicated antigen presenting cells which have the capacity to induce 
and orchestrate primary immune responses, immunological memory, and immunological 
tolerance (Banchereau, Brier & Caux, 2000).  At least three subsets of human DC are known.  
Myeloid CD34+ progenitors differentiate into CD14+ CD11+ dendritic cell precursor cells in 
the peripheral blood.  These cells give rise to dermal or interstitial dendritic cells.  The same 
myeloid CD34+ progenitors may differentiate also into CD14- CD11+ Langerhan precursors 
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that give rise to Langerhan cells in response to stimulation by granulocyte/macrophage 
colony-stimulating factor (GM-CSF), IL-4, and transforming growth factor (TGF)-β.  In 
addition lymphoid CD34+ progenitors can differentiate into CD14- CD11- IL-3R+ precussors 
in the blood (plasmacytoid T cells) and further differentiate into immature dendritic cells in 
the presence of IL-3 (Banchereau, et al., 2000; Pulendran, Maraskovsky & Banchereau, 
2001). 
 
In principle, immature dendritic cell, following encountering and capturing specific antigens, 
migrate to lymphoid tissues, where they mature and present the antigen in the context of the 
MHC to T helper cells and elicit specific immune responses (Banchereau, et al., 2000).  
Distinct dendritic cell subsets can initiate different Th responses; myeloid CD11+ DC usually 
promote Th1 type response while CD11- plasmacytoid dendritic cells promote Th2 type 
response (Pulendran, et al., 2001). 
 
The respective polarisation of the Th type response depends on the distinct subset type of the 
dendritic cell and its maturation stage, the cytokine profile of the micro-environment and the 
type of pathogen.  As the immune response evolves and the infection changes its dynamics, 
the initial given Th response may change accordingly through modifications in the function of 
the evolved DC (Pulendran, et al., 2001). 
 
Oral epithelial Langerhans cells are part of the dendritic cell family and are important 
members of the innate arm of the immune system (Cutler & Jotwani, 2004).  They are located 
in the basal and suprabasal layer of the epithelium and express on their cell membrane the 
following markers: MHC class II molecules, CD1a and CD4 glycoproteins, among others.  
Langerhan cells in its immature state, recognise and capture microbial antigens, then migrate 
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to regional lymph nodes via the lamina propia where they become mature dendritic cells 
expressing CD83 glycoprotein on the cell membrane.  The mature dendritic cells are efficient 
antigen presenting cells; following intracellular processing of the captured antigens, the 
resultant peptides are loaded on MHC class II molecules on the cell surface for presentation to 
CD4+ T cells.  As a result of this process, CD4+ T cell undergo activation, priming and 
antigen-specific clonal expansion (Cutler, et al., 2004). 
 
In immunocompetent subjects with chronic periodontitis there is an increase in the number of 
Langerhan cells in the pocket epithelium and in CD83 mature dendritic cells in the adjacent 
lamina propia (Cutler, et al., 2004).  In response to the challenge of the periodontopathic 
bacteria and the subsequent production of pro-inflammatory cytokines by other 
immunoregulatory cells, Langerhans cells are mobilised to the pocket epithelium, capturing 
the microbial antigens, migrate to lymph nodes as mature dendritic cells, presenting the 
captured antigen to naïve CD4+ T cells, and activate them.  These activated CD4+ T cells 
undergo differentiation and clonal expansion and migrate from the lymph node to the lamina 
propia of the pocket epithelium to take part in the local immune response against the 
periodontopathic bacteria.  These mature dendritic cells and activated T cells form lymphoid 
foci’s in the lamina propia of the periodontal pocket wall (Cutler, et al., 2004).  To these 
lymphoid foci in the lamina propria, Langerhan cells, in the presence of pro-inflammatory 
cytokines, migrate from the gingival epithelium, mature into CD83+ professional antigen 
presenting dendritic cells, and interact with memory CD4+ T cells without having first to 
migrate to the lymph nodes.  
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3.5  Immunopathogenic mechanisms of HIV infection 
 
The HIV virus is a member of the Retrovirus family.  The HIV genome consists of three 
major (Gag, Pol, Env) and six accessory (Tat, Rev, Vif, Vpr, Nef, Vpu) genes.  Pol codes for 
the major enzymes reverse transcriptase, Gag codes for internal structural proteins and Env 
codes for the evelope glycoprotein gp120 and transmembrane protein gp41.  HIV replication 
begins when gp120 protein binds to the CD4 receptor on the hosts T lymphocyte.  For HIV to 
fuse to, and enter its target cell efficiently, binding to a co-receptor is required.  The two 
major co-receptors for HIV are CCR5 and CXCR4.  HIV strains using CCR5 as a co-receptor 
are referred to as R5 viruses and strains that use the CXCR4 as a coreceptor are referred to as 
X4 viruses.  R5 viruses infect mainly macrophages and predominate during the initial stages 
of HIV disease, whereas the synctium inducing X4 variants emerge during a later stage of the 
infection (Yin, Jay & Grbic, 2007). 
 
HIV disease is a chronic, progressive disease with variable periods of clinical latency.  The 
hallmark of HIV disease is a profound immunodeficiency, resulting primarily from 
progressive demunition of CD4+ T cells.  The HIV-associated direct mechanisms causing 
depletion of CD4+ T cells include  accumulation of unintergrated reverse-transcribed viral 
DNA in the infected cell, synctium formation, increase in plasma membrane permeability,  
induction of apoptosis, and  budding of viruses from HIV infected cells.  Indirect mechanisms 
of HIV-induced depletion of CD4+ T cells include a CD8+ cytotoxic T cell response, 
mutation of HIV gene products and HIV-associated thymic dysfunction (Yin, et al., 2007; 
Feller & Lemmer, 2007b) 
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Continous budding of viruses from infected cells can cause cell membrane disruption with 
increased permeability resulting in death of the cell.  Specific HIV proteins can induce cell 
membrane permeability causing cell death.  Increased cellular toxicity is induced by the build-
up of unintergrated linear viral DNA in the infected cell.  HIV specific cytotoxic T-
lymphocytes (CTL) recognises the HIV-infected cells in an MHC class I restricted manner.  
This cell to cell contact activates the mechanisms for lysis of HIV-infected cells.  
Furthermore, HIV nef protein can induce apoptosis of bystander CD4+ T cells (Paranjape, 
2005).   
 
In addition to the CD4+ T-cell depletion, HIV infection is characterised by functional defects 
of macrophages.  Most of the HIV infected macrophages are found in tissues and not in the 
peripheral blood.  Monocytes and macrophages provide a safe vehicle for transport of HIV to 
various parts of the body, as well as function as a reservoir, whose output remains largely 
protected from the hosts defence mechanisms.  As the CD4+ T cell numbers decline parallel 
to the HIV disease progression,  macrophages may be the major vehicle of continued viral 
replication (Cotran, Kumar & Collins, 1999).    
 
Advanced HIV disease is characterised by defects of cytotoxic CD8+ T cell response.  The 
profound loss of CD4+ T cells in HIV infection has an impact on the CTL response.  For 
maturation of CD8+ cytotoxic T cells to occur, IL-2 is required.  IL-2 is secreted by HIV-
specific CD4+ and CD8+ T cells.  With the depletion of CD4+ T cells,  secretion of IL-2 is 
also diminished, resulting in an inability of CTL to control HIV replication (Altfeld & 
Rosenberg, 2000).  
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HIV progression is characterised by high levels of HIV viremia and a reduction in the number 
of CD8+ cytotoxic T cells.  Reduction of CD8+ cytotoxic T cells is a result of defects in 
maturation as well as clonal exhaustion (Northfield, Harcourt & Lucas, 2005).  CD8+ 
cytotoxic T cells  are chronically activated due to persistent exposure to high HIV levels.  
Disturbances in the maturation process of memory CD8+ T cells and premature loss of 
existing effector T cells is a  consequence of the chronic activation and excessive proliferation 
of  these cells (Appay & Rowland-Jones, 2002; Northfield, et al., 2005).  
 
As HIV disease advances, in the absence of highly active anti-retroviral treatment (HAART) 
and in the presence of persistent high plasma viral load,  HIV-seropositive subjects experience 
a shift from T-helper (Th)-1 dominant cellular immunity mediated by interleukin (IL)-2, IL-
12 and interferon-gamma to a Th-2 dominant humoral response mediated by IL-4, IL-5 and 
IL-10, and a suppressed Th-1 cytokine response (Imami, Antonopoulos & Hardy, 1999; 
Handa & Bingham, 2001).  This alteration in the cytokine network during the course of HIV 
disease promotes the dysregulation of immune responses and is associated with a number of 
inflammatory conditions. 
 
 
3.6 HIV disease and highly active antiretroviral treatment (HAART) 
 
With the introduction of highly active antiretroviral therapy (HAART) in 1996 as a standard 
of care in HIV-infected patients, there has been a decrease in the frequencies of HIV-
associated infections as well as a decrease in the incidence and prevalence of HIV-associated 
neoplasms (Palella, Delaney & Moorman, 1998).  Despite the mild toxicity and adverse 
effects of HAART, the combination of drugs comprising protease inhibitors and reverse 
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nucleoside inhibitors have turned HIV disease into a chronic, controllable disease (Monini, 
Sgadari & Barillari, 2003). 
 
HAART improves the immune function by suppressing HIV viral replication leading to an 
increase in the CD4+ T cell counts (Palella, et al., 1998; Douek, Picker & Koup, 2003) and 
resulting in an improved quality of life and prolonged survival (Palella, et al., 1998).  In 
patients receiving HAART, the recovery of CD4+ T cell count is associated with the decrease 
in HIV replication and occurs in two phases.  The first phase owing to the redistribution of T 
cells is associated with an increase in circulating memory T cells previously trapped in 
lymphoid tissue.  The second or the repopulation phase usually occurs a few months after the 
introduction of HAART and is characterised by the production of naïve T cells (Palella, et al., 
1998).     
 
Antiretroviral therapy is recommended for all patients with symptomatic or asymptomatic 
HIV infection with CD4+ T cell counts of ≤ 200 cells/mm³.  Potentially life-threatening 
conditions such as lymphoma or tuberculosis may be decreased with the initiation of 
antiretroviral therapy at this stage (Yeni, Hammer & Hirsch, 2004).  Generally, antiretroviral 
therapy is not recommended for patients having a CD4+ T cell count of >350 cells/mm³ due 
to significant drug toxicity and the development of metabolic disorders and cardiovascular 
diseases.  However, antiretroviral therapy is recommended in patients with a high viral load or 
a rapid diminution in CD4+ T cell counts even if their CD4+ T cell count is above 200 
cells/mm³ (Yeni, et al., 2004). 
 
The currently available antiretroviral regimens cannot eradicate the HIV infection.  This is 
due to the pool of latently infected CD4+ T cells established early in the course of HIV 
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infection and persists despite HAART-associated prolonged suppression of HIV replication 
(Chun, Stuyver & Mizell, 1997; Finzi, Hermankova & Pierson, 1997; Wong, Hezareh & 
Gunthard, 1997).  The goals of HAART include suppression of viral load, reconstitution of 
immune function, reduction of HIV-related morbidity and mortality and improvement in the 
quality of life (Finzi, et al., 1997; Wong, et al., 1997).   
 
Following the initiation of HAART, the immune system is partially reconstituted: there is a 
gain in the CD4+ T cell counts, an improvement in the functional competence of the 
immunoregulatory cells, and a shift from a predominant Th-2 type cytokine profile to a more 
normal balanced Th1/Th2 ratio (Finzi, et al., 1997). 
 
 
3.7 Chronic periodontitis and HIV infection 
 
The relationship between chronic periodontitis and HIV infection is not clear (Holmstrup, et 
al., 2002; Stanford, et al., 2003).  Some authors reported a higher prevalence of periodontal 
attachment loss and a more rapid progression of periodontal disease over time in HIV-
seropositive subjects compared to HIV-seronegative controls (Robinson, et al., 1996; Roberts, 
et al., 1997; McKaig, Thomas & Patton, 1998; Robinson, et al, 2000).  In addition it has been 
reported that a great portion of the periodontal attachment loss seen in HIV-seropositive 
subjects with chronic periodontitis is expressed in the form of localised recession, rather than 
the development of deep periodontal pockets as in chronic periodontitis in HIV- seronegative 
subjects (Robinson, et al., 1996; Robinson, 1998; McKaig, et al., 2000; Ryder, 2002).  
However, others failed to document differences between HIV-seropositive and -seronegative 
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subjects with chronic periodontitis regarding the natural course of the periodontal disease 
(Scheutz, et al., 1997; Matee, et al., 1999).  
 
Microbiological studies have failed to detect any major differences in the subgingival 
microbial flora of HIV-seropositive subjects compared to HIV-seronegative controls 
(Zambon, et al., 1990; Moore, et al., 1993) and the humoral immune response to the 
periodontopathic bacteria is similar in both groups of subjects (Yeung, et al., 2002). 
 
In HIV-seropositive subjects with chronic periodontitis there is a significant reduction in 
Langerhan cell numbers in the pocket epithelium, compared with HIV-seronegative subjects 
with chronic periodontitis (Myint, Yuan & Schenck, 2000).  It is therefore possible that the 
localised depletion of Langerhan cells in the oral epithelium of HIV-seropositive subjects may 
alter the local host immune response towards periodontopathic bacteria, and increase the 
susceptibility of the HIV-seropositive subjects to the development and progression of 
periodontal diseases (Myint, et al., 2000; Chou, Epstein & Cassol, 2000).  The oral mucosal 
Langerhan cells are the target of HIV, and HIV p17 structural protein can be detected in oral 
Langerhan cells of HIV-seropositive subjects, particularly in patients with high HIV viral 
load.  Such HIV-infected dendritic cells could be a target for a cytotoxic CD8+ T-cell 
response, resulting in the depletion of Langerhan cells in the HIV affected areas of the oral 
epithelium (Chou, et al., 2000). However, there is no evidence that this theoretical chain of 
events in fact promotes periodontal tissue destruction in HIV-seropositive subjects with 
chronic periodontitis. 
 
It is important to note that HIV-infected epithelial cells and HIV-infected Langerhan cells 
(Chou, et al., 2000) might represent a possible significant risk for HIV transmission through 
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oral fluids, especially in the presence of active periodontal disease.  Oral fluids contain saliva, 
epithelial and mononuclear cells, gingival crevicular serum transudate, and blood products 
(from active periodontal sites) which all might contain HIV.  This might have significant 
implications for public health issues related to transmission of HIV infection (Chou, et al., 
2000). 
 
HIV-seropositive subjects with periodontal disease have greater number of herpesviruses in 
periodontal pockets than HIV-seronegative control subjects with similar pocket depth.  
Chronic periodontitis in HIV-seropositive subjects is associated with a higher prevalence of 
single or combined infection of HHV 6, 7, 8 and EBV than chronic periodontitis in HIV-
seronegative subjects.  Moreover, HHV-8 is found solely in periodontal lesions of HIV-
seropositive subjects with chronic periodontitis.  However these findings do not imply that 
viruses have a specific role in the initiation and progression of chronic periodontitis in HIV-
seropositive subjects (Feller, Meyerov & Lemmer, 2007a; Slots, 2005). 
 
It is a well-known fact, that HIV infected subjects have increased frequencies of viral 
infections due to their immuno-suppression.  Therefore, it is not surprising that periodontal 
soft tissues of HIV-seropositive subjects harbour greater numbers of herpesviruses compared 
to periodontal soft tissues of HIV-seronegative subjects.  However, it is difficult to determine 
if the increase in number of herpesviruses in periodontal pockets of HIV-seropositive subjects 
with chronic periodontitis has any clinical or pathological significance regarding the 
development and progression of periodontal tissue breakdown (Feller, et al., 2007a). 
 
Candidal infection is associated with medical conditions characterised by suppressed cell 
mediated immunity including HIV infection, diabetes mellitus, immunosuppressive and 
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corticosteroid therapies among others (Feller, Buskin & Blignaut, 2005).  HIV-seropositive 
subjects with chronic periodontitis demonstrate a higher prevalence of candida in their 
subgingival microbial flora obtained from periodontal pockets compared to 
immunocompetent subjects with chronic periodontitis.  In one study (Jabra-Rizk, Ferreira & 
Sabet, 2001), 82% of HIV-seropositive examined subjects with periodontitis were positive for 
oral yeasts, and 66% of them harboured candida species in their subgingival samples 
(periodontal pockets >5mm).  However the authors did not specify what type of periodontal 
disease was involved. 
 
One can assume that the increased number of candida species in the periodontal pockets of 
HIV-seropositive subjects with chronic periodontitis has the potential to promote the local 
inflammatory process and to interfere with the local host immune response in the periodontal 
tissues.  The outcome of such a process might be an exacerbation of the existing inflammatory 
process caused by the periodontopathic bacteria resulting in accelerated periodontal tissue 
breakdown.  However there is no direct evidence to substantiate such an assumption (Feller, 
et al., 2005). 
 
 3.8 Wound healing and HIV infection 
 
Wound healing is a dynamic continium process, comprising several overlapping phases that 
encompass coagulation, inflammation (early and late stages), parenchymal and mesenchymal 
cell proliferation (granulation tissue phase), epithelisation, maturation and remodeling.  This 
process is clearly a multifactorial one involving complex interaction between 
immunoinflammatory cells (macrophages, monocytes, lymphocytes, dendritic cells, 
polymorphonuclear leukocytes, etc), mucosal resident cells (epithelial cells, fibroblasts, 
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osteoblasts, etc), and is orchestrated by cytokines, growth factors and other biological 
mediators in the micro-environment (Sedlarik, 1997; Monaco & Lawrence, 2003).  
  
Clinical studies have failed to demonstrate that HIV-associated immune suppression leads to 
an increased incidence of impairment in wound healing (Luck, Logan & Benson, 1996).  This 
can be explained by the fact that CD4+ T cells do not play a critical rôle (unlike 
monocytes/macrophages) in wound healing.  In principle lymphocytes are observed in the 
wound healing process in the granulation tissue phase, approximately at the fifth day 
following injury (Park & Barbul, 2004).  Animal studies on wound healing suggest that 
depletion of CD8+ T cells result in greater wound-breaking strengths and collagen synthesis, 
while depletion of CD4+ T cells has no effect on either mechanical strength or collagen 
formation.  However, an overall depletion of T cells result in reduction in mechanical strength 
and collagen content of the wound (Park, et al., 2004). 
 
In HIV-seropositive subjects free of pre-operative contamination, the incidence of wound   
infection following orthopaedic implant surgery is similar to that of HIV-seronegative 
controls, and low CD4 + T cell count does not seem to affect the incidence of post operative 
infection.  However, when there is pre-operative contamination, the incidence of infection in 
HIV-seropositive subjects increases markedly compared to HIV-seronegative subjects with 
pre-operative contamination (Harrison, Lewis & Lavy, 2002).  
 
HIV-seropositive subjects with CD4+ T cell counts lower than 100 cells/mm³ receiving 
emergency (palliative) and elective (curative) surgery will heal properly, but with 3-4 weeks 
delay, as long as opportunistic infection and underlying HIV-related malignancies are 
controlled.  HIV-seropositive subjects who undergo anorectal surgery and laparotomy have 
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higher frequencies of impairment of wound healing than HIV-seronegative control subjects.  
It seems that surgical procedures performed on sites that harbour high bacterial loads 
(anorectal surgery, internal fixation of open fracture, laparotomy), may have higher risk for 
wound infection and delayed wound healing (Harrison, et al., 2002). 
 
Clinical studies of HIV-seropositive subjects undergoing oral surgery, failed to identify any 
significant deficit in wound healing.  Post-tooth extraction complications are uncommon in 
HIV-seropositive subjects, and these subjects do not experience an increased incidence of 
delayed healing when compared to HIV-seronegative subjects (Porter, Scully & Luker, 1993), 
and post operative antibiotics are not associated with less complications (Dodson, 1997).   
 
One can deduct from these findings that the healing capacity of the periodontium remains 
functionally normal during HIV infection.  Therefore it is probable that during chronic 
periodontitis, the healing potential of the diseased periodontal tissues remain very much 
unchanged in HIV-seropositive subjects, compared to immunocompetent subjects with 
chronic periodontitis.  Moreover, following periodontal treatment, including different types of 
periodontal surgery, the response to treatment is the same in HIV-seropositive subjects and 
immunocompetent subjects (Dodson, 1997). 
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CHAPTER 4 
 
4.0   MATERIALS AND METHODS 
 
4.1 Subject population 
 
Ethical approval was obtained from the University of Limpopo and University of 
Witwatersrand, Johannesburg.  After obtaining an informed consent, 60 subjects, 30 HIV- 
seropositive and 30 healthy control subjects (presumed HIV-seronegative) with chronic 
periodontitis were recruited for this study.  All participants were black persons from the  
Ga-Rankuwa area in South Africa (34 females, 26 males) between the ages of 18 and 45 years 
belonging to a similar socioeconomic background.  The gender of the participants is shown in 
Table 1. 
 
The groups of HIV-seropositive subjects were composed of 16 subjects receiving highly 
active anti-retroviral therapy (HAART) and 14 HAART-naïve subjects at the time of 
diagnosis of their chronic periodontitis.  The HIV-serostatus was confirmed by enzyme-linked 
immunosorbent assay (ELISA) and western blot.  The CD4+ T cell counts were performed for 
13 subjects that had given informed consent.  Six HIV-seropositive subjects had CD4+ T cell 
counts below 200 cells/mm3.   
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4.2 Periodontal health status  
 
Chronic periodontitis was diagnosed by a clinical examination and radiographic evidence of 
periodontal attachment loss by a single clinician (RK).  Subjects were diagnosed with chronic 
periodontitis when at least three sites had pockets with probing depth ≥ 5mm and/or had 
gingival recession and there was radiographic evidence of alveolar bone loss (Figure 1).  The 
periodontal indices measured were pocket depth (PD) (Figure 2), gingival recession (GR) 
(Figure 3), plaque index (PI) and bleeding index (BI).  Periodontal PD measurements were 
taken at six sites per tooth (mesio-buccal, mid-buccal, disto-buccal, disto-lingual, mid-lingual 
and mesio-lingual) and the GR measurement were taken at two tooth sites (buccal or lingual) 
around the erupted teeth, excluding third molars and residual roots.  The periodontal 
examination forms of all participants in this study are shown in appendix 2.  The periodontal 
pocket depth and gingival recession measurements were done with a periodontal probe with 
Williams markings.  Bleeding index per mouth was calculated by summing the measurements 
of the gingival tooth sites bleeding on periodontal probing (one possible measurement per 
tooth: bleeding or not bleeding) and dividing it by the number of teeth present in the mouth 
(appendix 1).  The plaque index per mouth was calculated (after using disclosing solution) by 
summing the measurements of plaque present at four tooth sites (mesial, buccal, distal and 
lingual) and dividing it, by the number of teeth multiplied by four (appendix 2).   
 
In this study, pocket depth (PD), gingival recession (GR), plaque index (PI) and bleeding 
index (BI) were compared by HIV-serostatus, the use of HAART and CD4+ T cell counts.  
CD4+ T cell counts were stratified into the following groups; CD4+ T cell count < 200 
cells/mm³, CD4+ T cell counts 200 – 500 cells/mm³  and CD4+ T cell count > 500 cells/mm³.  
HAART was defined as the use of at least two nucleoside reverse transcriptase inhibitors with 
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either a non-nucleoside reverse transcriptase inhibitor or a “boosted” protease inhibitor 
(Mortality and causes of death, 2005).  CD4+ T cell counts were available for eight HIV-
seropositive subjects using HAART and for five HAART-naïve subjects.  There were only 
eight subjects that admitted to smoking, and because of this small number, smoking was not 
correlated to the periodontal indices. 
 
No attempt was made to differentiate between active chronic periodontitis sites (suppuration 
from pockets, bleeding on probing, continuous loss of periodontal attachment) and stable 
chronic periodontitis sites with evidence of previous loss of periodontal attachment. 
 
For the purpose of this study a mean pocket depth value per mouth and a mean gingival 
recession value per mouth were calculated in order to enable an easy comparison of these two 
important periodontal indices between the studied and the control group of patients. 
 
The mean pocket depth per tooth was calculated by summing the measurements per tooth and 
dividing by the number of measurements.  The mean pocket depth per mouth (per participant) 
was calculated by summing all the mean pocket depth per tooth in the mouth and dividing it 
by the number of teeth.  The mean gingival recession per mouth was calculated by summing 
the measurements of the recessions of the involved teeth and dividing it by the number of 
teeth affected by recession.   
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Fig. 1   Pan x-ray showing moderate alveolar bone loss present in chronic periodontitis 
 
 
 
 
Fig. 2 Periodontal Probing 
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Fig. 3   Photograph showing gingival recession on mandibular 31, 32 and 41 
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4.3 Statistical analysis 
 
The statistical test in the present study was used in other similar studies reported in the 
literature and recommended by a statistic expert (Prof Fatti).  The statistical analysis was 
performed by the researcher (RK), and supervised by the statistician.  The results of the 
statistical tests were analysed by the researcher and her supervisors and approved by the 
statistician.    
 
All data were entered into the Microsoft Excel program and analysed using its data analysis 
package.  Programs for performing ANOVA, t-tests, Pearson Correlation coefficients and 
histograms were performed to conduct statistical hypothesis tests and explore associations.   
P values of < 0.05 were regarded as statistically significant.   
 
Single factor analysis of variance was used to test for differences in the periodontal indices 
between the healthy control subjects and the HIV-seropositive subjects with chronic 
periodontitis.  The two-sample t-test was employed to test the differences in the periodontal 
indices between the HIV-seropositive HAART-naïve subjects and the HIV-seropositive 
subjects using HAART.  The Pearson Correlation coefficient was used to test if there were 
significant relationships between the periodontal indices of the HIV-seropositive subjects to 
the log CD4+ T cell count. 
 
A log transformation of the CD4+ T cell count was calculated to correct for its skew 
distribution, and for the different scales of measurement between these counts and the 
periodontal indices. 
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CHAPTER 5 
 
5.0 RESULTS 
 
When all participants were evaluated, there was no association between HIV-serostatus and 
periodontal indices.  HIV-seropositive and control subjects with chronic periodontitis had 
similar mean PD, GR,  PI and BI (Table 1), and gender had no influence on the results (data 
not shown).  The mean periodontal indices were compared between HIV-seropositive and 
control subjects (Figures 4-7) using ANOVA and the mean P-values were as follows: P = 
0.23 for PD, P = 0.82 for GR, P = 0.65 for PI and P = 0.59 for BI.  Clearly none of them 
indicate significance at the P < 0.05 level (Table 2).   
 
HIV-seropositive subjects using HAART with chronic periodontitis, and HAART-naïve 
subjects with chronic periodontitis had similar mean GR, PI and BI (Table 3).  When 
periodontal indices were analysed using the t-test comparing HIV-seropositive subjects using 
HAART, and HAART-naïve subjects (Table 4), there was no statistical differences regarding 
mean GR (P=0.92), PI (P=0.32) and BI (P=0.53).  However, the mean PD in HAART-naïve 
seropositive subjects was slightly greater than in HIV-seropositive subjects using HAART 
(P=0.01).  The mean PD in the HAART-naïve seropositive subjects was 3.36mm vs 3.07mm 
in HIV-seropositive subjects using HAART.   
 
Pearson Correlation coefficient of mean PD in relation to CD4+ T cell count in the HIV-
seropositive  HAART-naïve group of subjects showed a significant negative correlation  
(P =  -0.947), but there was no correlation between the mean GR values and the CD4+ T cell 
counts in the same group (P=0.303) (Appendix 2).   
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For the HIV-seropositive subjects using HAART the Pearson Correlation coefficient test 
failed to show significant statistical relationships between CD4+ T cell count and mean PD 
(P=0.903) and mean GR (P=0.312) in HIV-seropositive subjects using HAART. 
 
Unexpectedly, the mean CD4+ T cell count was higher in the HAART-naïve group of 
subjects than HIV-seropositive subjects using HAART.  However, the CD4+ T cell counts 
were available only for a small number of subjects, eight subjects in the HAART-naïve group 
and five subjects in the HIV-seropositive subjects using HAART (Table 5), and the late 
introduction of HAART in HIV-seropositive subjects in South Africa could be responsible for 
these mean CD4+ T cell counts (Table 5). 
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Table 1   Epidemiological features and periodontal indices of HIV-seropositive subjects  
    with chronic periodontitis, and control subjects with chronic periodontitis 
 
 Presumably HIV-
seronegative control 
subjects with chronic 
periodontitis 
HIV-seropositive 
subjects with chronic 
periodontitis 
Females 14 20 
Males  16 10 
Smokers 5 3 
Pocket depths 
Mean 
STDEV* 
 
3.196mm 
0.58 
 
3.205mm 
0.32 
Gingival recession 
Mean 
STDEV* 
 
1.53mm 
 
0.89 
 
1.66mm 
 
0.71 
 
Number of gingival 
recessions 
STDEV* 
195 
 
 
5.11 
 
202 
 
 
5.46 
Plaque Index 
Mean 
STDEV* 
 
75.21% 
 
23.6 
 
75.59% 
 
20.16 
Bleeding Index 
Mean 
STDEV* 
 
50.03% 
 
19.4 
 
47.3% 
 
23.25 
*STDEV – standard deviation 
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Table 2   Mean P-values for the different periodontal indices compared between  
                HIV-seropositive and healthy control subjects using ANOVA  
 
Periodontal indices P-value 
Pocket depth (PD) 0.23 
Gingival recession (GR) 0.82 
Plaque index (PI) 0.65 
Bleeding index (BI) 0.59 
None of them indicate significance at the P<0.05 level.  
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Table 3   Epidemiological features, periodontal indices and immunological indices 
of HIV-seropositive subjects using HAART, of HAART-naïve HIV-seropositive      
subjects, and of control subjects.  All subjects had chronic periodontitis 
 
 Presumably HIV-
seronegative 
control subjects 
with chronic 
periodontitis 
HIV-seropositive 
subjects using 
HAART with 
chronic 
periodontitis 
HAART-näive 
HIV-
seropositive 
subjects with 
chronic 
periodontitis 
Females 14 12 8 
Males 16 4 6 
Smokers 5 2 1 
Pocket depths 
Mean 
STDEV* 
 
3.196 
0.58 
 
3.069 
0.28 
 
3.359 
0.30 
Gingival recession 
Mean 
STDEV* 
 
1.53 
0.89 
 
1.67 
0.79 
 
 
 
1.64 
0.64 
Number of 
gingival recessions 
STDEV* 
195 
 
5.11 
100 
 
4.14 
102 
 
3.56 
Plaque index 
Mean 
STDEV* 
 
75.21% 
23.6 
 
71.85% 
20.4 
 
79.34% 
26.1 
Bleeding index 
Mean 
STDEV* 
 
50.03% 
23.25 
 
42.53% 
18.3 
 
52.05% 
22.1 
CD4+ Count 
Mean 
STDEV* 
 
Not available 
 
171.63cell/mm³ 
108.94 
 
257.44cell/mm³ 
171.25 
*STDEV – standard deviation 
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Table 4   Mean P-values for the different periodontal indices compared between 
HIV-seropositive subjects using HAART and HAART-naïve seropositive 
subjects using the t-test 
 
Periodontal indices P-value 
Pocket depth (PD) 0.01* 
Gingival recession (GR) 0.92 
Plaque index (PI) 0.32 
Bleeding index (BI) 0.53 
*Significant at the P<0.05 level.  The mean PD in HAART-naïve seropositive subjects was 
slightly greater than in HIV-seropositive subjects using HAART. 
 
 
 
Table 5   The categories of CD4+ T cell levels of the HIV-seropostive subjects using  
                HAART, and HIV-seropositive HAART-naïve subjects.    
    
 HIV-seropositive 
subjects using HAART 
HIV-seropositive 
HAART-naïve subjects 
CD4+ count < 200 4 2 
CD4+ count 200 - 500  4 2 
CD4+ count > 500 0 1 
Mean CD4+ Count 172cell/mm³ 257cell/mm³ 
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Fig. 4   Mean pocket depth in mm in HIV-serpositive and  
            control subjects 
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Fig. 5   Mean gingival recession sites in HIV-seropositive 
            and control subjects 
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Fig. 6   Mean number of gingival recession sites in HIV-seropositive 
            and control subjects 
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Fig. 7   Mean plaque index and bleeding index in HIV-seropositive 
            and control subjects 
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CHAPTER 6 
 
6.0   DISCUSSION 
 
Some investigators reported that periodontal disease in HIV-seropositive subjects is 
characterised by increased periodontal attachment loss and accelerated periodontal disease 
progression compared to periodontal disease in HIV-seronegative subjects (Robinson, et al., 
1996; Robinson, et al., 2000).  It was also suggested that the attachment loss in HIV-
seropositive subjects with chronic periodontitis is associated with GR rather than deep 
periodontal pocket formation (Robinson, et al., 1996; Robinson, 1998; McKaig, et al., 2000).  
This study fails to document any differences in the mean PD, GR, PI and BI between HIV-
seropositive and control subjects with chronic periodontitis.  This conforms with other studies 
that documented similiar clinical manifestations and natural course of chronic periodontitis in 
HIV-seropositive and –seronegative subjects  (Holmstrup & Westergaard, 1994; Scheutz, et 
al., 1997; Persson, Hollender & Persson, 1998; Matee, et al., 1999).   
 
In this study the mean GR was similiar in HIV-seropositive and control subjects and between 
HIV-seropositive HAART-näive and HIV-seropositive subjects using HAART.  Moreover, 
the mean GR values were not associated with low CD4+ T cell counts.  This is in 
disagreement with the findings of McKaig, et al., (2000) and Lamster, et al., (1997) that found 
a negative correlation between CD4+ T cell count and increased frequency of recession. 
McKaig, et al., (2000) reported that recession in HIV-seropositive patients with chronic 
periodontitis is more likely to occur with CD4+ T-cell count <200 cells/mm³ than with CD4+ 
T-cell count between 200-499 cells/mm³, is associated with co-existing oral candidiasis, and 
is not related to traumatic tooth-brushing.  From our clinical experience, and supported by the 
 38
results of this study, HIV-seropositive subjects with chronic periodontitis do not have an 
increase in the number of gingival sites and/or severity of gingival recession, and low CD4+ T 
cell counts is not a risk factor associated with increased frequency and severity of GR. 
 
This study demonstrates that both HIV-seropositive and control subjects with chronic 
periodontitis, have similar mean PD, GR, PI and BI measurements, and that HIV-infection 
dose not pose a greater risk for accelerated periodontal attachment loss.  This is supported by 
other studies (Stanford, et al., 2003; Khongkunthian, Grote & Isaratanan, 2001).  Therefore 
the periodontal treatment modalities for chronic periodontitis in HIV-seropositive subjects 
should be same as for chronic periodontitis in immuno-competent subjects.  If indeed some 
HIV-seropositive subjects demonstrate increased levels of attachment loss, it may be the 
result of periodontal disease activity that took place before they contracted the HIV disease.  
In order to determine the timing of the initiation and progression of the periodontal 
attachment loss in relation to HIV infection one would need reliable clinical and radiological 
records of the periodontium documenting the alveolar bone loss before and after HIV 
contraction (Feller, Wood & Raubenheimer, 2006).   
 
The profound HIV-associated immune suppression does not seem to increase the risk for the 
development of chronic periodontitis.  The diminution in the CD4+ T cell counts, the 
dysregulation in the cytokine network and the qualitative defects of macrophages, monocytes, 
polymorphonuclear leukocytes, dendritic cells and T lymphocytes do not predispose the HIV-
seropositive subject to increased colonisation of periodontopathic bacteria (Gonçalves, 
Ferreira & Silva, 2004; Gonçalves, Ferreira & Souza, 2007), to delayed wound healing of the 
oral tissues (Porter, et al., 1993) to increased incidence of wound infection following oral 
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surgery and periodontal treatment (Dodson, 1997), and to periodontal tissue destruction 
(Schuetz, et al., 1997; Holmstrup, et al., 1994;  Matee, et al., 1999). 
 
Since the periodontal tissue destruction in chronic periodontitis is mediated mainly by host 
derived cellular immune responses (Offenbacher, 1996), and since these mechanisms are to a 
great extent suppressed in HIV-infection, HIV-seropositive subjects with chronic periodontitis 
may show reduced rather than exaggerated periodontal tissue destruction, compared to 
immuno-competent subjects with chronic periodontitis.  Moreover, active periodontal disease 
associated with periodontal attachment loss is related mainly to a Th1 cytokine profile 
(Takeichi, et al., 2000; Taubman, et al., 2001).  However, in advanced HIV disease, in the 
absence of HAART, there is a dysregulation in the cytokine network characterised by a shift 
from Th1 predominant cytokines to a Th2 cytokine profile that is less associated with 
periodontal tissue destruction.  This only reinforces the concept that HIV-associated immune 
dysregulation may not contribute to the development of chronic periodontitis. 
 
Taking into consideration the profound immune suppression associated with HIV infection 
one would have expected that HIV-seropositive subjects with low CD4+ T cell counts would 
be infected with higher frequencies of periodontopathic bacteria and will show an increase 
incidence of wound infection following oral surgery, compared to HIV-seropositive subjects.  
However, this is not the case.  HIV-seropositive and –seronegative subjects show similar 
types and quantities of periodontopathic bacteria in their subgingival microbiota, similar 
incidence of wound healing infection and similar wound healing capacity (Feller, et al., 2006).   
 
HIV-seropositive subjects with periodontal disease harbour similiar periodontopathic bacteria 
in their subgingival plaque to that of immunocompetent subjects with periodontal disease  
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(Moore, et al., 1993).  However, HIV-seropositive subjects demonstrate bacterial species in 
their subgingival microbiota that are usually not associated with periodontal disease.  These 
opportunistic micro-organisms include E. faecalis, A. baumannii and Pseudomonas 
aeruginosa, and most probably are associated with HIV-related immunosuppression; and with 
the circumstances that HIV-seropositive subjects are frequently treated in a hospital 
environment; and with the regular use of antimicrobials to prevent opportunistic infections 
(Gonçalves, et al., 2005).   
 
HIV-seropositive subjects do not demonstrate impaired wound healing capacity (Luck, et al., 
1996) or increase incidence of wound infection following oral surgery (Porter, et al., 1993) 
compared to HIV-seronegative subjects.  The wound healing process is complex and involves 
interaction between multiple factors including macrophages, dendritic cells, 
polymorphonuclear leukocytes and mucosal resident cells (epithelial cells, fibroblasts and 
osteoblasts), cytokines and growth factors (Monaco, et al., 2003).  While macrophages and 
growth factors are the driving force behind the wound healing process (Monaco, et al., 2003; 
Sedlarik, 1997), CD4+ T cells do not play a critical role in this process (Park, et al., 2004).  
Therefore, in spite of some impairment in the function of macrophages and the alteration in 
the cytokine network in HIV-infection, this does not seem to influence the healing capacity of 
the periodontium. 
 
There is an inverse association between CD4+ T cell counts and the frequencies of HIV-
associated oral lesions, in particular when the CD4+ T cell count is lower than 200 cells/mm³, 
regardless of the use of HAART.  However, HIV-seropositive subjects using HAART have a 
significant lower prevalence of HIV-associated oral lesions compared to HAART-naïve HIV-
seropositive subjects (Tappuni & Fleming, 2001). 
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The use of HAART in HIV-seropositive subjects has brought about a decrease in the 
prevalence and severity of chronic periodontitis (Tappuni, et al., 2001;  Ryder, 2002).  HIV-
seropositive subjects with chronic periodontitis using HAART demonstrate reduced counts of 
periodontopathic bacteria in their subgingival plaque; and the periodontal tissues of such 
subjects show reduced inflammation and periodontal attachment loss, compared to HIV-
seronegative subjects with chronic periodontitis (Gonçalves, et al., 2007). 
 
Even severely compromised HIV-seropositive subjects using HAART with low CD4+ T cell 
counts (AIDS) and having chronic periodontitis demonstrate similar compositions of 
periodontopathic bacteria in their subgingival microbiota compared to HIV-seronegative 
subjects with chronic periodontitis (Gonçalves, et al., 2004).  It is possible that HAART-
associated reconstitution of parts of the immune responses is successful in controlling the 
colonisation of the periodontopathic pathogens, even in the presence of low CD4+ T cell 
counts (Gonçalves, et al., 2004; Gonçalves, et al., 2007).  It is also possible that some 
components of the anti-retroviral drugs have an anti-inflammatory and anti-bacterial 
properties therefore further facilitating the host to control the periodontal tissue destruction.        
 
This study has a few limitations.  Firstly, the control group was composed of healthy subjects, 
with unconfirmed HIV-serostatus, presumably HIV-seronegative.  For various reasons, people 
in the Ga-Rankuwa area in South Africa are reluctant to have voluntary HIV testing and most 
probably some of the control subjects were asymptomatic HIV-seropositive unaware of their 
HIV-serostatus.  This is a realistic possibility bringing into consideration that it is estimated 
that 16.2% of South Africans between the ages of 15 and 49 years are HIV-seropositive 
(Mortality and causes of death, 2005).  However, since there were no differences in the 
periodontal indices between HIV-seropositive subjects and control subjects with chronic 
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periodontitis, the unconfirmed HIV-status of the control group does not pose a significant 
shortcoming.     
 
Secondly, the HIV-seropositive sample size with known CD4+ T cell counts was small.  The 
CD4+ T cell counts were available for only 13 HIV-seropositive subjects, eight subjects using 
HAART and five HAART-naïve subjects.  With such a small examined sample, the results of 
the statistical analysis regarding CD4+ T cell counts and the periodontal indices could have 
been biased.  In this study the correlation coefficient test between PD and CD4+ T cell count 
in the HIV-seropositive HAART-naïve group of subjects showed a significant negative 
correlation (P<0.01).  This differs from other studies that documented a positive correlation 
between CD4+ T cell counts and PD measurements in HIV-seropositive subjects; and that 
HIV-seropositive subjects with a healthy periodontium that are using HAART have a lower 
CD4+ T cell counts, while HIV-seropositive subjects using HAART with chronic 
periodontitis have higher CD4+ T cell counts (Vastardis, Yukna & Fidel, 2003).  These 
differences between the results of our study and the other might be owing to our small sample 
of subjects with CD4+ T cell counts available.   
 
In this study the mean CD4+ T cell counts found in HAART-naïve group of subjects 
(257cells/mm³) was higher than in HIV-seropositive using HAART group of subjects 
(172cells/mm³).  On first thought this is a paradoxical finding that should be attributed to 
biased statistical results associated with the small number of subjects with available CD4+ T 
cell counts.  However, on second consideration, this finding might be real.  In South Africa, a 
considerable number of people with suggestive HIV-associated conditions refuse to undergo 
serological testing for HIV, and at times prefer to receive treatment by traditional healers.  
This leads to the eventual diagnosis of HIV infection and the initiation of HAART late in the 
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natural course of HIV disease when the CD4+ T cell count is already very low 
(<200cells/mm³).  In addition, in the South African context, HIV-seropositive subjects from 
low socioeconomic backgrounds that are dependant on government health department 
services, are entitled to start HAART only when their CD4+ T cell counts is below 
200cells/mm³.  This circumstance often leads to the initiation of HAART when the CD4+ T 
cell count dropped already substantially below the 200 cells/mm³ mark; and it is a well 
established fact that starting HAART when the CD4+ T cell count is very low, will lead to a 
reduced reconstitution of CD4+ T cell numbers compared to starting HAART at higher levels 
of CD4+ T cell.  Therefore, the HIV-seropositive subjects using HAART in this study had a 
lower CD4+ T cell count compared to the CD4+ T cell count of HIV-seropositive HAART-
naïve subjects. 
 
In contrast, three of the five HIV-seropositive HAART-naïve subjects with known CD4+ T 
cell counts had CD4+ T cells above 200 cells/mm³ and therefore not entitled to HAART while 
the other two subjects had CD4+ T cells below 200cells/mm³, were recently diagnosed with 
HIV, and were in the process of starting HAART or being treated by a traditional healer.  Of 
interest, the other seven HIV-seropositive subjects with unknown CD4+ T cell counts did not 
consent to a blood test to check their CD4+ T cell count, quite a frequent behavioural 
phenomenon experienced in the Ga-Rankuwa area in South Africa. 
 
In this study the mean PD in the HAART-naïve HIV-seropositive subjects with chronic 
periodontitis was slightly greater than in the HIV-seropositive subjects using HAART 
(P=0.01).   This differs from other studies that show that the use of HAART is associated 
with reduced severity of periodontal disease (Gonçalves, et al., 2007; Ryder, 2002; Patton, 
Phelan & Ramos-Gomez, 2002).  However, if one brings into consideration that in this study 
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the mean CD4+ T cell count in the group of HIV-seropositive subjects using HAART was 
lower than in the group of HIV-seropositive HAART-naïve subjects, it conforms to other 
studies that report a positive correlation between PD measurements and CD4+ T cell counts 
(Vastardis, et al., 2003).      
   
In order to have a more reliable result one needs to have a larger sample size with available 
CD4+ T cell counts and definitive information regarding the HIV-serostatus of the control 
group. 
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CHAPTER 7 
 
7.0 CONCLUSION 
 
In this somewhat limited study, HIV-seropositive subjects with chronic periodontitis show 
similar clinical manifestations of periodontal disease to those of the control subjects with 
chronic periodontitis with no differences in the mean PD, GR, PI and BI, and a low CD4+ T 
cell count is not a risk factor for increased frequency and severity of gingival recession.  The 
conclusion is that the treatment of chronic periodontitis in HIV-seropositive and HIV-
seronegative subjects should be the same.  
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